# US 2021/0275545 A1 · Method of treating cancer preferably characterized by expression of a fusion protein comprising a member of the e-twenty-six family by administering an agent that inhibits the synthesis and/or activity of cortisol > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0275545 A1 - Document ID: US20210275545A1 - Status: Published application - Kind: A1 - Application number: 17/325,355 - Filed: 2021-05-20 - Published: 2021-09-09 - Earliest claimed: 2018-11-21 - Assignees: Yeda Research and Development Co. Ltd. - Applicants: Yeda Research and Development Co. Ltd. - Inventors: Yosef YARDEN; Swati SRIVASTAVA - Web page: https://patentgrep.com/patent/US20210275545A1 ## CPC - A61K 31/567: substituted in position 17 alpha, e.g. mestranol, norethandrolone - A61K 31/03: aromatic - A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole - A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil - A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline - A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone - A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine - A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin - A61P 35/00: Antineoplastic agents - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - C12Q 2600/158: Expression markers - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES ## Abstract A method of treating a cancer selected from the group consisting of a myeloid malignancy, a lymphoid malignancy and Ewing's sarcoma is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent that inhibits the synthesis and/or activity of cortisol. ## Claims ### Claim 1 A method of treating a cancer selected from the group consisting of a myeloid malignancy, a lymphoid malignancy and Ewing's sarcoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that inhibits the synthesis and/or activity of cortisol, thereby treating the cancer. ### Claim 2 A method of treating a subject having a cancer characterized by expression of a fusion protein which comprises a member of the E-twenty-six (ETS) family, the method comprising: (a) analyzing in a sample of the subject for the presence of a genomic ETS rearrangement; and (b) administering to the subject a therapeutically effective amount of an agent that inhibits the synthesis and/or activity of cortisol upon identification of said genomic ETS rearrangement, thereby treating the cancer. ### Claim 3 A method of treating a subject having a cancer characterized by expression of a fusion protein which comprises a member of the E-twenty-six (ETS) family, the method comprising: (a) analyzing in a sample of the subject for the presence of a genomic ETS rearrangement; and (b) administering to the subject a therapeutically effective amount of an agent that inhibits the synthesis and/or activity of cortisol upon identification of said genomic ETS rearrangement, or administering to the subject a therapeutically effective amount of an anti-cancer agent other than an agent that inhibits the synthesis and/or activity of cortisol upon identification of an absence of said genomic ETS rearrangement, thereby treating the cancer. ### Claim 4 (depends on 2) The method of claim 2, wherein said sample comprises a fluid sample. ### Claim 5 (depends on 4) The method of claim 4, wherein said fluid sample is selected from the group consisting of whole blood, plasma, serum and urine. ### Claim 6 (depends on 2) The method of claim 2, wherein said sample comprises a tissue sample. ### Claim 7 (depends on 2) The method of claim 2, wherein said analyzing for the presence of said genomic ETS rearrangement is effected at the DNA level. ### Claim 8 (depends on 2) The method of claim 2, wherein said analyzing for the presence of said genomic ETS rearrangement is effected at the RNA level. ### Claim 9 (depends on 2) The method of claim 2, wherein said analyzing for the presence of said genomic ETS rearrangement is effected at the protein level. ### Claim 10 (depends on 2) The method of claim 2, wherein said cancer is selected from the group consisting of myeloid malignancy, a lymphoid malignancy, prostate cancer and Ewing's sarcoma. ### Claim 11 (depends on 2) The method of claim 2, wherein said member of the ETS family is ERG or FL1. ### Claim 12 (depends on 2) The method of claim 2, wherein said agent that inhibits the activity of cortisol is a glucocorticoid receptor antagonist. ### Claim 13 (depends on 12) The method of claim 12, wherein said glucocorticoid receptor antagonist is a selective inhibitor of the glucocorticoid receptor. ### Claim 14 (depends on 13) The method of claim 13, wherein said selective inhibitor of the glucocorticoid receptor is C113176 or C108297. ### Claim 15 (depends on 12) The method of claim 12, wherein said glucocorticoid receptor antagonist is mifepristone. ### Claim 16 (depends on 2) The method of claim 2, wherein said agent that inhibits synthesis of cortisol is selected from the group consisting of metyrapone ketoconazole, levoketoconazole, LCI699, mitotane, aminoglutethimide and etomidate. ### Claim 17 (depends on 16) The method or agent of claim 16, wherein said agent is metyrapone. ### Claim 18 (depends on 2) The method of claim 2, wherein said agent that inhibits synthesis of cortisol is a polynucleotide agent or a proteinaceous agent that targets a component of the cortisol synthesis pathway.